About
Janpix develops ultra-selective STAT inhibitors designed to treat hematological tumors and glioblastomas by modulating immune cells and the tumor micro-environment to facilitate tumor eradication.
Explore Janpix's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.